These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

645 related articles for article (PubMed ID: 26598537)

  • 1. Prognostic value of programmed-death-1 receptor (PD-1) and its ligand 1 (PD-L1) in testicular germ cell tumors.
    Cierna Z; Mego M; Miskovska V; Machalekova K; Chovanec M; Svetlovska D; Hainova K; Rejlekova K; Macak D; Spanik S; Ondrus D; Kajo K; Mardiak J; Babal P
    Ann Oncol; 2016 Feb; 27(2):300-5. PubMed ID: 26598537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Svetlovska D; Kalavska K; Rejlekova K; Spanik S; Kajo K; Babal P; Mardiak J; Mego M
    Oncotarget; 2017 Mar; 8(13):21794-21805. PubMed ID: 28423520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of programmed death ligand-1 (PD-L1) in metastatic and postchemotherapy viable testicular germ cell tumors.
    Al-Hogbani M; Duguay J; Wagner DC; Haferkamp A; Joubert P; Frees S; Rendon R; Power N; Périgny M; Toren P
    Urol Oncol; 2021 May; 39(5):303.e1-303.e8. PubMed ID: 33685799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in PD-L1-Expressing Macrophages and Immune Microenvironment in Testicular Germ Cell Tumors.
    Sadigh S; Farahani SJ; Shah A; Vaughn D; Lal P
    Am J Clin Pathol; 2020 Feb; 153(3):387-395. PubMed ID: 31802108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between glutathione S-transferases M1 expression and treatment outcome in germ cell tumor patients.
    Mego M; Kalavska K; Horak S; Hyblova M; Kolnikova G; Novotna V; Majtanova K; Minarik G; Kucerova L; Cierna Z
    Neoplasma; 2024 Aug; 71(4):374-386. PubMed ID: 39267534
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PARP expression in germ cell tumours.
    Mego M; Cierna Z; Svetlovska D; Macak D; Machalekova K; Miskovska V; Chovanec M; Usakova V; Obertova J; Babal P; Mardiak J
    J Clin Pathol; 2013 Jul; 66(7):607-12. PubMed ID: 23486608
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent PD-L1 expression in testicular germ cell tumors.
    Fankhauser CD; Curioni-Fontecedro A; Allmann V; Beyer J; Tischler V; Sulser T; Moch H; Bode PK
    Br J Cancer; 2015 Jul; 113(3):411-3. PubMed ID: 26171934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation.
    Zschäbitz S; Lasitschka F; Hadaschik B; Hofheinz RD; Jentsch-Ullrich K; Grüner M; Jäger D; Grüllich C
    Eur J Cancer; 2017 May; 76():1-7. PubMed ID: 28262583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topoisomerase II alpha expression in testicular germ cell tumors.
    Dimov ND; Zynger DL; Luan C; Kozlowski JM; Yang XJ
    Urology; 2007 May; 69(5):955-61. PubMed ID: 17482942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. βcatenin is a marker of poor clinical characteristics and suppressed immune infiltration in testicular germ cell tumors.
    Chovanec M; Cierna Z; Miskovska V; Machalekova K; Kalavska K; Rejlekova K; Svetlovska D; Macak D; Spanik S; Kajo K; Babal P; Mego M; Mardiak J
    BMC Cancer; 2018 Nov; 18(1):1062. PubMed ID: 30390643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Response of a Patient to Anti-PD-1 Immunotherapy and the Immune Landscape of Testicular Germ Cell Tumors.
    Shah S; Ward JE; Bao R; Hall CR; Brockstein BE; Luke JJ
    Cancer Immunol Res; 2016 Nov; 4(11):903-909. PubMed ID: 27638840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The expression of programmed cell death ligand 1 (PD-L1) involves in the clinicopathologic characteristics and prognostic implications of testicular germ cell tumor (TGCT): a systematic review and meta-analysis.
    Li P; Zhong Y; Zhang M; Zheng Y; Peng W
    Transl Cancer Res; 2024 Aug; 13(8):3944-3959. PubMed ID: 39262473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysgerminomas: germ cell tumors exhibit high expression of PD-L1 and associated with high TILs and good prognosis.
    Alwosaibai K; Alruwaii ZI; Mashhour M; Almsned FM; Asraf R; Alrsheedy W; Alessa A; Almohanna H; Selwi W; Azam F
    Sci Rep; 2024 Oct; 14(1):24191. PubMed ID: 39406772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical significance of programmed death 1/programmed death ligand 1 pathway in gastric neuroendocrine carcinomas.
    Yang MW; Fu XL; Jiang YS; Chen XJ; Tao LY; Yang JY; Huo YM; Liu W; Zhang JF; Liu PF; Liu Q; Hua R; Zhang ZG; Sun YW; Liu DJ
    World J Gastroenterol; 2019 Apr; 25(14):1684-1696. PubMed ID: 31011254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of programmed death-1 and programmed death-ligand 1 expression in patients with esophageal squamous cell carcinoma.
    Chen K; Cheng G; Zhang F; Zhang N; Li D; Jin J; Wu J; Ying L; Mao W; Su D
    Oncotarget; 2016 May; 7(21):30772-80. PubMed ID: 27120796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
    Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
    Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testicular germ cell tumor: a comprehensive review.
    Batool A; Karimi N; Wu XN; Chen SR; Liu YX
    Cell Mol Life Sci; 2019 May; 76(9):1713-1727. PubMed ID: 30671589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II study of avelumab in multiple relapsed/refractory germ cell cancer.
    Mego M; Svetlovska D; Chovanec M; Rečkova M; Rejlekova K; Obertova J; Palacka P; Sycova-Mila Z; De Giorgi U; Mardiak J
    Invest New Drugs; 2019 Aug; 37(4):748-754. PubMed ID: 31152292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PD-L1 expression in testicular germ cell tumors undergoing spontaneous regression.
    Novak I; Tomić M; Mulabdić D; Pezelj I; Čiček S; Tomašković I; Sinčić N; Krušlin B; Ulamec M
    Biomol Biomed; 2024 Oct; 24(6):1751-1760. PubMed ID: 38943678
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.